Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial

Safe and effective vaccines are still urgently needed to cope with the ongoing COVID-19 pandemic. Recently, we developed a recombinant COVID-19 vaccine (V-01) containing fusion protein (IFN-PADRE-RBD-Fc dimer) as antigen verified to induce protective immunity against SARS-CoV-2 challenge in pre-clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jikai, Hu, Zhongyu, He, Jianfeng, Liao, Yuyi, Li, Yuan, Pei, Rongjuan, Fang, Xin, Zeng, Peiyu, Fan, Renfeng, Ou, Zhiqiang, Deng, Jinglong, Zhou, Jian, Guan, Wuxiang, Min, Yuanqin, Deng, Fei, Peng, Hua, Zhang, Zheng, Feng, Chunyan, Xin, Baobao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366678/
https://www.ncbi.nlm.nih.gov/pubmed/34197281
http://dx.doi.org/10.1080/22221751.2021.1951126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366678/
https://www.ncbi.nlm.nih.gov/pubmed/34197281
http://dx.doi.org/10.1080/22221751.2021.1951126

Ejemplares similares